<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874923</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0034</org_study_id>
    <nct_id>NCT03874923</nct_id>
  </id_info>
  <brief_title>Comparison of 250 ml Versus 500 ml of Fluid Challenge</brief_title>
  <acronym>KOBIAS</acronym>
  <official_title>Comparison of 250 ml Versus 500 ml of Fluid Challenge on Oxygen Consumption in Critical Care Patients: an Open Label Multicentre Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of fluid challenge is to increase oxygen delivery (DO2) in order to
      improve/restore tissue oxygen consuption (VO2). However the fluid challenge volume to
      administer stills in debate, some studies recommend to administer 250 mL. Previous studies
      suggested that 500 mL of fluid challenge administration may improve cardiac output and oxygen
      delivery. The relation between the amount of fluid expansion and oxygen delivery and oxygen
      consumption was not yet been studied in a randomized study in critical care patients. This is
      the purpose of this study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VO2 after fluid challenge</measure>
    <time_frame>30 minutes after fluid challenge.</time_frame>
    <description>Tissue oxygen consumption (VO2) after fluid challenge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 after fluid challenge</measure>
    <time_frame>60 minutes after fluid challenge.</time_frame>
    <description>Tissue oxygen consumption (VO2) after fluid challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of arterial lactate concentration from baseline</measure>
    <time_frame>30 minutes after fluid challenge.</time_frame>
    <description>Baseline is the measurement of arterial lactate concentration immediately after fluid challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of arterial lactate concentration from baseline</measure>
    <time_frame>60 minutes after fluid challenge.</time_frame>
    <description>Baseline is the measurement of arterial lactate concentration immediately after fluid challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Immediately, 30 and 60 minutes after fluid challenge.</time_frame>
    <description>Cardiac output after fluid challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory variation of stroke volume</measure>
    <time_frame>Immediately, 30 and 60 minutes after fluid challenge.</time_frame>
    <description>Respiratory variation of stroke volume after fluid challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Immediately, 30 and 60 minutes after fluid challenge.</time_frame>
    <description>PaO2/FiO2 ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen) after fluid challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory variation of the pulse pressure</measure>
    <time_frame>30 and 60 minutes after fluid challenge.</time_frame>
    <description>Respiratory variation of the pulse pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke volume variation with passive leg raising (PLV)</measure>
    <time_frame>30 and 60 minutes after fluid challenge.</time_frame>
    <description>Stroke volume variation with passive leg raising (PLV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic heart function (LVEF)</measure>
    <time_frame>Immediately, 30 and 60 minutes after fluid challenge.</time_frame>
    <description>Systolic heart function (LVEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic heart function</measure>
    <time_frame>Immediately, 30 and 60 minutes after fluid challenge.</time_frame>
    <description>Diastolic heart function (E, A, E', A', S' waves)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Fluid Challenge</condition>
  <condition>Oxygen Consumption</condition>
  <condition>Critical Care</condition>
  <arm_group>
    <arm_group_label>250 mL of fluid challenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mL of fluid challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid challenge</intervention_name>
    <description>After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.</description>
    <arm_group_label>250 mL of fluid challenge</arm_group_label>
    <arm_group_label>500 mL of fluid challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient for whom the physician in charge decided to infuse fluid challenge because of
             signs of acute circulatory failure (systolic arterial blood pressure &lt; 90mmHg, and/or
             mean arterial blood pressure&lt; 65 mmHg, and/or the need of vasopressive amine infusion,
             and/or skin motling, and/or diuresis &lt;0.5 mL/kg/h for more than 2 hours, and/or
             arterial lactate level&gt;2mmol/L.

          -  Echogenic patient

          -  Patient with a Stroke Volume (SV) variation with passive leg raising (PLR) more than
             10%.

          -  Patient with regular sinus rythm.

          -  Patient who received protocol information.

        Exclusion Criteria:

          -  Age Under 18-year-old.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Abou-Arab, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osama Abou-Arab, Dr</last_name>
    <phone>(33) 322087836</phone>
    <email>abouarab.osama@chu-amiens.fr</email>
  </overall_contact>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluid expansion</keyword>
  <keyword>oxygen delivery</keyword>
  <keyword>tissue perfusion</keyword>
  <keyword>cardiac output</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

